Jazz Pharmaceuticals Reports Q3 Revenue Beat Amid Significant Non-GAAP EPS Miss
Jazz Pharmaceuticals (JAZZ) reported third-quarter financial results characterized by a significant divergence between top and bottom lines. While the company achieved revenue of $1.24 billion, representing a 9.7% year-over-year increase and beating consensus estimates by $30 million, its Non-GAAP earnings per share (EPS) fell sharply to -$3.88. This figure missed analyst expectations by $1.50. The substantial EPS miss was driven primarily by a massive $755 million charge related to In-Process Research and Development (IPR&D). Despite the bottom-line volatility, the company provided full-year revenue guidance of $4.775 billion to $4.850 billion, which sits above the previous consensus range of $4.6 billion to $4.75 billion.
Tickers: $JAZZ
Topics: earnings miss financial guidance IPR&D charge revenue beat